L
Lexaria Bioscience Corp.
LEXXCIK 0001348362NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Aug 31
Period
FY 2025
Revenue
$705.9K
Net Income
$-11.90M
Total Assets
$4.18M
Equity
$2.99M
Shares Out
24.79M
Op. Cash Flow
$-10.45M
Business
Lexaria Bioscience Corp. is a biotechnology company that develops and licenses DehydraTECH, a patented drug delivery technology that enhances the bioavailability of active pharmaceutical ingredients through oral formulations. The company offers licensing arrangements for DehydraTECH-enhanced products across pharmaceuticals, nutraceuticals, and consumer goods, with applications in GLP-1/GIP drugs for diabetes and weight loss, CBD for hypertension, nicotine delivery, vitamins, and pain medications. Lexaria conducts research and development programs and licenses its technology through wholly-owned and majority-owned subsidiaries to third-party manufacturers and distributors globally.
Summary from 10-K filed 2025-11-28
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-08-31 | FY 2024 2024-08-31 | FY 2023 2023-08-31 | FY 2022 2022-08-31 | FY 2021 2021-08-31 |
|---|---|---|---|---|---|---|
| Revenue | 705,923 | 464,278 | 226,208 | 255,397 | 722,738 | |
| Cost of goods sold | 2,720 | 4,822 | 31,500 | 71,841 | 175,346 | |
| Gross profit | 703,203 | 459,456 | 194,708 | 183,556 | 547,392 | |
| Research and development | 8 | 2 | 4 | 2 | 1 | |
| General and administrative | 4 | 4 | 3 | 5 | 5 | |
| Total operating expenses | 13 | 6 | 7 | 7 | 6 | |
| Loss from operations | −12 | −6 | −7 | −7 | −6 | |
| Interest income | 3,017 | 14,311 | — | — | — | |
| Unrealized loss on marketable securities | −33,714 | −69,835 | — | — | — | |
| Total other income (loss) | −30,697 | −55,524 | — | — | — | |
| Net loss | −12 | −6 | −7 | −7 | — | |
| Less: Net loss attributable to non-controlling interest | −9,593 | −13,309 | −47,626 | −114,329 | −159,142 | |
| Net loss attributable to Lexaria shareholders | −12 | −6 | −7 | −7 | −4 | |
| Foreign currency translation adjustment | −50,519 | −19,816 | — | — | — | |
| Total comprehensive loss | −12 | −6 | −7 | — | — | |
| Basic and diluted loss per share | −0.66 | −0.47 | −1.01 | — | — | |
| - Basic and diluted | 18 | 12 | 7 | — | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-08-31 | FY 2024 2024-08-31 | FY 2023 2023-08-31 | FY 2022 2022-08-31 | FY 2021 2021-08-31 |
|---|---|---|---|---|---|---|
| Cash | 2 | 6 | 1 | 6 | 11 | |
| Short-term investments | 143,267 | 0 | — | — | — | |
| Marketable securities | 22,093 | 55,807 | 125,642 | 347,335 | 833,841 | |
| Accounts receivable | 368,358 | 154,477 | 126,686 | 201,784 | 342,401 | |
| Prepaid expenses and other current assets | 1 | 1 | 546,783 | — | — | |
| Total Current Assets | 3 | 8 | 2 | 7 | 12 | |
| Long-term receivables | 64,013 | 63,575 | 48,559 | — | — | |
| Right of use assets | 106,816 | 134,843 | 167,446 | 52,444 | 91,041 | |
| Intellectual property, net | 307,818 | 516,676 | — | — | — | |
| Property & equipment, net | 228,129 | 254,709 | 254,143 | 315,505 | 368,213 | |
| Total Non-current Assets | 706,776 | 969,803 | 932,773 | 856,411 | 823,877 | |
| TOTAL ASSETS | 4 | 9 | 3 | 8 | 13 | |
| Accounts payable and accrued liabilities | 1 | 1 | 239,941 | 151,449 | 105,496 | |
| Deferred revenue | 0 | 4,963 | — | — | — | |
| Lease liability, current | 30,417 | 28,047 | — | — | — | |
| Total Current Liabilities | 1 | 1 | 267,735 | 194,036 | 153,276 | |
| Lease liabilities - non-current | 78,903 | 109,319 | — | — | — | |
| TOTAL LIABILITIES | 2 | 1 | 403,908 | 201,437 | 203,265 | |
| Share Capital Authorized: 220,000,000 common voting shares with a par value of $0.001 per share Common shares issued and outstanding: 19,559,179 and 15,810,205 at August 31, 2025 and August 31, 2024, respectively | 19,559 | 15,810 | 8,091 | 5,951 | 5,727 | |
| Additional paid-in capital | 67 | 60 | 49 | 47 | 45 | |
| Accumulated Deficit | −63 | −52 | −46 | −39 | −32 | |
| Accumulated other comprehensive loss | −70,335 | −19,816 | 0 | — | — | |
| Equity attributable to shareholders of Lexaria | 3 | 8 | 3 | 8 | 13 | |
| Non-controlling Interest | −386,942 | −377,349 | — | — | — | |
| Total Stockholders' Equity | 3 | 8 | 3 | 8 | 13 | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 4 | 9 | 3 | 8 | 13 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-08-31 | FY 2024 2024-08-31 | FY 2023 2023-08-31 | FY 2022 2022-08-31 | FY 2021 2021-08-31 |
|---|---|---|---|---|---|---|
| Net loss | −12 | −6 | −7 | — | — | |
| Stock based compensation | 859,494 | 492,236 | 170,382 | 752,591 | 410,007 | |
| Depreciation and amortization | 87,825 | 76,153 | 145,397 | 102,718 | 111,718 | |
| Impairment loss | 247,364 | 57,836 | — | — | — | |
| Bad debt expense | 0 | 7,760 | — | 0 | 50,500 | |
| Noncash lease expense | 28,027 | 32,603 | — | — | — | |
| Lease accretion | 9,047 | 6,672 | — | — | — | |
| Accounts receivable | −213,881 | −35,551 | 26,539 | −137,491 | 189,580 | |
| Prepaid expenses and deposits | 55,313 | −641,034 | — | — | — | |
| Long-term receivables | −438 | −15,016 | — | — | — | |
| Accounts payable and accrued liabilities | 396,637 | 826,468 | 88,492 | 50,726 | 13,803 | |
| Operating lease liability | −37,093 | −33,273 | −44,814 | 0 | — | |
| Deferred revenue | −4,962 | 4,962 | 0 | 0 | −44,255 | |
| Net cash used in operating activities | −10 | −5 | −6 | −5 | −4 | |
| Short-term investments | −143,267 | 0 | — | — | — | |
| Additions to intellectual property | −75,106 | −145,591 | −135,862 | −131,448 | −79,493 | |
| Purchase of equipment | −24,646 | −43,014 | −33,748 | −49,192 | — | |
| Net cash used in investing activities | −243,019 | −188,605 | −169,610 | −180,640 | 193,880 | |
| Proceeds from exercise of stock options | 0 | 2,875 | — | — | — | |
| Proceeds from shares sold for cash | 6 | 4 | — | — | — | |
| Proceeds from exercise of warrants | 0 | 6 | — | 0 | 4 | |
| Net cash provided by financing activities | 6 | 10 | 2 | −44,600 | 13 | |
| Effect of exchange rate changes on cash | −50,519 | −19,816 | — | — | — | |
| Net change in cash for the period | −5 | 5 | −4 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Lexaria Bioscience Corp.'s CIK number?
Lexaria Bioscience Corp.'s SEC CIK number is 0001348362 (1348362). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Lexaria Bioscience Corp.'s SEC filings?
All of Lexaria Bioscience Corp.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.